FM
Frazier Management Portfolio holdings
AUM
$1.12M
This Quarter Return
+43.09%
1 Year Return
+150.24%
3 Year Return
+430.4%
5 Year Return
+1,926.83%
10 Year Return
–
AUM
$187M
AUM Growth
+$187M
(+136%)
Cap. Flow
+$112M
Cap. Flow
% of AUM
59.63%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
1
Increased
2
Reduced
–
Closed
–
Top Buys
| 1 |
AnaptysBio
ANAB
|
$102M |
| 2 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
$9.07M |
| 3 |
RXDX
Ignyta, Inc.
RXDX
|
$201K |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AnaptysBio
ANAB
$569M
| $102M | 54.68% | +3,688,448 | New | +$102M |
|
2
Collegium Pharmaceutical
COLL
$1.22B
| $19M | 10.14% | 1,887,332 | – | – |
|
3
Amicus Therapeutics
FOLD
$2.34B
| $18.5M | 9.9% | 2,600,014 | – | – |
|
4
Iovance Biotherapeutics
IOVA
$807M
| $16.3M | 8.71% | 2,188,331 | – | – |
|
|
SRRA
5
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $12.4M | 6.63% | 8,112,121 +5,925,926 | +271% | +$9.07M |
|
6
Cidara Therapeutics
CDTX
$1.66B
| $10.2M | 5.47% | 1,312,258 | – | – |
|
|
RXDX
7
DELISTED
Ignyta, Inc.
RXDX
| $8.37M | 4.47% | 973,693 +23,327 | +2% | +$201K |
|